NFE2L2 and B-cell chronic lymphocytic leukemia: that promoted expression of Nrf2 in CLL cells mitigates ROS and incudes cell resistance against chemotherapy through activation of mTORC1 and NF-κB pathways corresponding to the p65 phosphorylation which generally leads to the cell survival [11].